✦ LIBER ✦

Clinical Assessment and Efficacy of Once-Yearly Intravenous Zoledronic Acid in Korean Osteoporosis Patients

✍ Scribed by Park, Y.-S.; Lee, J.-H.; Kim, H.-S.

Book ID: 125827967
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 42 KB
Volume: 17
Category: Article
ISSN: 1094-6950
DOI: 10.1016/j.jocd.2014.04.115

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and Safety of a Once-Yearly Int

Efficacy and Safety of a Once-Yearly Intravenous Zoledronic Acid 5 mg for Fracture Prevention in Elderly Postmenopausal Women with Osteoporosis Aged 75 and Older

✍ Steven Boonen; Dennis M. Black; Cathleen S. Colón-Emeric; Richard Eastell; Jay S 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 226 KB

Efficacy of intravenous zoledronic acid

Efficacy of intravenous zoledronic acid in the prevention and treatment of osteoporosis: A meta–analysis

✍ Zhang, Jun; Wang, Ran; Zhao, Yi-Lei; Sun, Xiao-Hui; Zhao, Hong-Xing; Tan, Lu; Ch 📂 Article 📅 2012 🏛 Medknow Publications 🌐 English ⚖ 355 KB

Intravenous zoledronic acid and oral ale

Intravenous zoledronic acid and oral alendronate in patients with a low trauma fracture: experience from an osteoporosis clinic

✍ S. J. Craig; P. P. Youssef; J. H. Vaile; L. Sullivan; J. F. Bleasel 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 139 KB

A community-based clinical trial of Intr

A community-based clinical trial of Intra-Venous zOledRonic acid once Yearly in comparison to oral bisphosphonates in postmenopausal women with osteoporosis: The IVORY trial: Methodological considerations

✍ Jacques P. Brown; J.D. Adachi; D.L. Kendler; R. Rigal; G. Deutsch; J.M. Leclerc 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 171 KB

Bone material properties in actively bon

Bone material properties in actively bone-forming trabeculae in postmenopausal women with osteoporosis after three years of treatment with once-yearly Zoledronic acid

✍ Sonja Gamsjaeger; Birgit Buchinger; Elizabeth Zwettler; Robert Recker; Dennis Bl 📂 Article 📅 2010 🏛 American Society for Bone and Mineral Research 🌐 English ⚖ 473 KB

Zoledronic acid (ZOL), a third-generation aminobisphosphonate, showed pronounced antifracture efficacy in a phase III clinical trial [Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly-Pivotal Fracture Trial (HORIZON-PFT)] when administered yearly (5-mg infusions of ZOL), produci

Efficacy and safety of a once-yearly i.v

Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: A randomized, multicenter, double-blind, active-controlled study

✍ Eric S Orwoll; Paul D Miller; Jonathan D Adachi; Jacques Brown; Robert A Adler; 📂 Article 📅 2010 🏛 American Society for Bone and Mineral Research 🌐 English ⚖ 216 KB

## Abstract Zoledronic acid (ZOL) has shown beneficial effects on bone turnover and bone mineral density (BMD) in postmenopausal osteoporosis. This study compared the efficacy and safety of a once‐yearly i.v. infusion of ZOL with weekly oral alendronate (ALN) in men with osteoporosis. In this multi